Anakinra for rheumatoid arthritis
National Institute for Clinical Excellence
Record ID 32003001213
English
Authors' objectives:
To provide guidance on the use of anakinra for rheumatoid arthritis.
Authors' recommendations:
Guidance:
1.1 On the balance of its clinical benefits and cost effectiveness, anakinra is not recommended for the treatment of rheumatoid arthritis, except in the context of a controlled, long-term clinical study.
1.2 Patients currently receiving anakinra for rheumatoid arthritis may suffer loss of well-being if their treatment were discontinued at a time they did not anticipate. Therefore, patients should continue therapy with anakinra until they and their consultant consider it is appropriate to stop.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2003
URL for published report:
http://www.nice.org.uk/cat.asp?c=94670
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Arthritis, Rheumatoid
- Methotrexate
- Sialoglycoproteins
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.